These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1976975)

  • 1. Relation between serum cholesterol and diabetic nephropathy.
    Ekberg G; Grefberg N; Larsson O; Vaara I
    Lancet; 1990 Oct; 336(8720):954. PubMed ID: 1976975
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk factors for progression of diabetic nephropathy.
    Yokota C; Kimura G; Inenaga T; Kawano Y; Matsuoka H; Omae T
    Am J Nephrol; 1995; 15(6):488-92. PubMed ID: 8546170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephropathy in a hypercholesterolemic mouse model with streptozotocin-induced diabetes.
    Hammad SM; Hazen-Martin DJ; Sohn M; Eldridge L; Powell-Braxton L; Won W; Lyons TJ
    Kidney Blood Press Res; 2003; 26(5-6):351-61. PubMed ID: 14610340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians.
    Hirata-Dulas CA; Rith-Najarian SJ; McIntyre MC; Ross C; Dahl DC; Keane WF; Kasiske BL
    Clin Nephrol; 1996 Aug; 46(2):92-8. PubMed ID: 8869785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of lipid abnormalities to progression of renal damage in essential hypertension, insulin-dependent and non insulin-dependent diabetes mellitus.
    Walker WG
    Miner Electrolyte Metab; 1993; 19(3):137-43. PubMed ID: 8232100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy.
    Krolewski AS; Warram JH; Christlieb AR
    Kidney Int Suppl; 1994 Feb; 45():S125-31. PubMed ID: 8158881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study.
    Gall MA; Hougaard P; Borch-Johnsen K; Parving HH
    BMJ; 1997 Mar; 314(7083):783-8. PubMed ID: 9080995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL cholesterol and risk of diabetic nephropathy in patient with type 1 diabetes: A meta-analysis of cohort studies.
    Chen Y; Zhi Y; Li C; Liu Y; Zhang L; Wang Y; Che K
    Diabetes Res Clin Pract; 2016 Dec; 122():84-91. PubMed ID: 27816683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lovastatin in the treatment of hypercholesterolemia in nephrotic syndrome due to diabetic nephropathy stage IV-V.
    Biesenbach G; Zazgornik J
    Clin Nephrol; 1992 Jun; 37(6):274-9. PubMed ID: 1638777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment with pravastatin of dyslipidemia associated with diabetic nephropathy].
    Robles NR; Ruiz-Calero R; Coronado M; Escola JM; Sánchez Casado E
    An Med Interna; 1998 Nov; 15(11):572-5. PubMed ID: 9882852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosylated proteins in diabetic nephropathy.
    Ramzy M; Habib M; el-Sheemy N; Dunn M; Iskander I; Samney S; Doss SH
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():649-54. PubMed ID: 2581243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetic nephropathy--risk factors and incidences].
    Fujita T; Ohi H
    Nihon Rinsho; 1997 Oct; 55 Suppl():789-94. PubMed ID: 9392198
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential role of lipids in the progression of diabetic nephropathy.
    Krämer-Guth A; Quaschning T; Greiber S; Wanner C
    Clin Nephrol; 1996 Oct; 46(4):262-5. PubMed ID: 8905213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Who will develop diabetic nephropathy?].
    Forsblom C; Harjutsalo V; Groop PH
    Duodecim; 2014; 130(12):1253-9. PubMed ID: 25016671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Low birth weight--increased risk of diabetic nephropathies?].
    Rossing P; Tarnow L; Nielsen FS; Hansen BV; Brenner BM; Parving HH
    Ugeskr Laeger; 1996 Dec; 159(1):41-4. PubMed ID: 9012073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia.
    Wada T; Muso E; Maruyama S; Hara A; Furuichi K; Yoshimura K; Miyazaki M; Sato E; Abe M; Shibagaki Y; Narita I; Yokoyama H; Mori N; Yuzawa Y; Matsubara T; Tsukamoto T; Wada J; Ito T; Masutani K; Tsuruya K; Fujimoto S; Tsuda A; Suzuki H; Kasuno K; Terada Y; Nakata T; Iino N; Kobayashi S
    Clin Exp Nephrol; 2018 Jun; 22(3):591-596. PubMed ID: 29080119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tobacco and end stage diabetic nephropathy.
    Stegmayr B; Lithner F
    Br Med J (Clin Res Ed); 1987 Sep; 295(6598):581-2. PubMed ID: 3117242
    [No Abstract]   [Full Text] [Related]  

  • 18. [Perinatal factors can be risk factors of diabetic nephropathy].
    Rudberg S
    Lakartidningen; 2000 Jan; 97(4):317-9. PubMed ID: 10684225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of homocysteine to early nephropathy in patients with Type 2 diabetes.
    Li J; Shi M; Zhang H; Yan L; Xie M; Zhuang L; Zhu Y; Chen J
    Clin Nephrol; 2012 Apr; 77(4):305-10. PubMed ID: 22445474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic nephropathy in children.
    Bogdanovic R
    Nephrol Dial Transplant; 2001; 16 Suppl 6():120-2. PubMed ID: 11568268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.